The European Commission approved the use of Gilead Sciences' Tybost, or cobicistat, as a boosting agent for certain protease inhibitors used in the treatment of HIV/AIDS. Tybost is part of Gilead's combination HIV-1 pill Stribild.
Gilead's HIV treatment booster Tybost gets EU approval
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|